NCT02470858 - Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG

LDV/SOF+ASV

Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.

DRUG

SOF+DCV+SMV

Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.

DRUG

SOF+DCV+ASV

Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.

Trial Locations (1)

00852

Humanity and Health GI and Liver Centre, Hong Kong

All Listed Sponsors

collaborator

Beijing 302 Hospital

OTHER

collaborator

Emory University

OTHER

lead

Humanity and Health Research Centre

OTHER